Mechanisms of Paclitaxel-induced peripheral neuropathy

Document Type : Review Articles

Authors

1 Department of pharmacology and toxicology, faculty of pharmacy, Minia university, Egypt

2 Pharmacology and Experimental Oncology Unit, National Cancer Institute, Cairo University, Egypt.

3 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, Egypt

4 Department of Pharmacology & Toxicology, Faculty of Pharmacy, Minia University, El-Minia 61519, Egypt

Abstract

Peripheral neuropathy is a common adverse effect associated with the use of a group of chemotherapeutic agents including paclitaxel (PTX) which negatively affect the quality of life of cancer survivors. In addition, it is considered as a dose-limiting side effect that hinder completion of appropriate chemotherapy regimen. In spite of 27 years of research in mechanisms of PTX neuropathy, there is no approved therapy for prevention of PTX-induced peripheral neuropathy (PIPN). Thus, there is a continuous need to characterize the possible mechanisms associates with PIPN in order to find appropriate targeted therapy for this clinical problem. In this review, we summarized most of the recent findings of the cellular targets implicated in PIPN.
 

Keywords

Main Subjects

Journal of Advanced Biomedical and Pharmaceutical Sciences
Volume 6, Issue 1
January 2023
Pages 25-35

Files

Share

How to cite

Statistics